SNSE
Sensei Biotherapeutics, Inc.Healthcare·Biotechnology
$21.14
$28M market cap
Revenue
$0.0M
Free Cash Flow
$-14.6M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal an
2-Year Price History
$17.79+36.7%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -170.6 | -170.6 | -170.2 | -10.7 | -10.7 | -0.0 | 202.8 | 1.0 | 1.3 | -380.1% | -- | -- |
| Act | 2025-Q4 | 0.0 | -4.7 | -5.0 | -4.7 | -3.9 | -3.9 | -0.0 | 21.2 | 1.5 | 1.3 | -262.6% | -1560.0x | -- |
Valuation & Metrics
Market Stats
Price$21.14
Market Cap$28M
Enterprise Value$-173M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-51.5%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-174.9M
Free Cash Flow$-14.6M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-321.3%
WC Change % Rev0.0%
Interest Coverage-58435.7x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.8M
Days to Cover27.1
Change (vs Prior)-2.5%
Need at least 2 settlement dates for chart
Employees
Headcount14
Revenue / Employee$0
Gross Profit / Employee$-9,496,929
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
328.5%(+328.4% YoY)
26 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
3.1%(+3.1% YoY)
3 filers
Vanguard, iShares, SPDR
Market makers
1.4%(+1.4% YoY)
2 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Vivo Capital, LLC | $22.8M | $31.52 | +$22.8M | +$22.8M | -7.0% | $1.20B |
| Woodline Partners LP | $11.4M | $31.52 | +$11.4M | +$11.4M | -0.1% | $26.43B |
| Cormorant Asset Management, LLC | $9.7M | $31.52 | +$9.7M | +$9.7M | -2.4% | $1.95B |
| MILLENNIUM MANAGEMENT LLC | $4.6M | $31.52 | +$4.6M | +$4.6M | -0.5% | $127.40B |
| FRANKLIN RESOURCES INC | $4.2M | $31.52 | +$4.2M | +$4.2M | -0.2% | $403.03B |
| STEMPOINT CAPITAL LP | $4.2M | $31.52 | +$4.2M | +$4.2M | +1.4% | $520M |
| Caligan Partners LP | $4.0M | $31.52 | +$4.0M | +$4.0M | +6.8% | $1.41B |
| Trails Edge Capital Partners, LP | $3.9M | $31.52 | +$3.9M | +$3.9M | +11.9% | $425M |
| MARSHALL WACE, LLP | $2.1M | $31.52 | +$2.1M | +$2.1M | +0.6% | $92.71B |
| GOLDMAN SACHS GROUP INC | $1.9M | $31.52 | +$1.9M | +$1.9M | -0.2% | $760.93B |
| HRT FINANCIAL LP | $1.8M | $31.52 | +$1.8M | +$1.8M | -0.6% | $39.46B |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $1.1M | $31.52 | +$1.1M | +$1.1M | -9.1% | $3.69B |
| BANK OF AMERICA CORP /DE/ | $1.0M | $31.09 | +$1.0M | +$1.0M | -0.1% | $1.36T |
| RENAISSANCE TECHNOLOGIES LLC | $1.0M | $23.63 | +$647K | +$1.0M | +1.2% | $63.91B |
| Logos Global Management LP | $946K | $31.52 | +$946K | +$946K | -1.6% | $1.94B |
| BOOTHBAY FUND MANAGEMENT, LLC | $823K | $31.52 | +$823K | +$823K | -0.4% | $4.25B |
| Brevan Howard Capital Management LP | $641K | $31.52 | +$641K | +$641K | -0.9% | $9.34B |
| FRED ALGER MANAGEMENT, LLC | $578K | $31.52 | +$578K | +$578K | -0.3% | $22.77B |
| BALYASNY ASSET MANAGEMENT LLC | $511K | $31.52 | +$511K | +$511K | -0.4% | $48.01B |
| Catalio Capital Management, LP | $464K | $8.58 | +$0 | +$464K | +3.2% | $479M |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-1.49%
avg per quarter
Holders (ex-self)
-1.53%
excl. this stock
Buyers (this Q)
-1.51%
26 buyers · $0.08B in
Sellers (this Q)
-8.85%
1 sellers · $0.00B out
alpha coverage: 99% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-6.8%
how holders react when this stock falls
On quiet Qs
-6.2%
−10% to +10% baseline
On rallies (+10%+)
-6.0%
how they react when this stock rises
Holders' portfolio flow this Q
-12.0%
outflows — trims may be forced
Sellers' portfolio flow this Q
-10.9%
Sellers shed AUM broadly — partly forced.
Biggest decreases this quarter
New buyers this quarter
Vivo Capital, LLC+$0.02Bα-7.0Woodline Partners LP+$0.01Bα-0.1Cormorant Asset Management, LLC+$0.01Bα-2.4MILLENNIUM MANAGEMENT LLC+$0.00Bα-0.5FRANKLIN RESOURCES INC+$0.00Bα-0.2STEMPOINT CAPITAL LP+$0.00Bα+1.4Caligan Partners LP+$0.00Bα+6.8Trails Edge Capital Partners, LP+$0.00Bα+11.9MARSHALL WACE, LLP+$0.00Bα+0.6GOLDMAN SACHS GROUP INC+$0.00Bα-0.2
Top-5 holders · 66.3%
Vivo Capital, LLC--
Woodline Partners LP--
Cormorant Asset Management, LLC--
MILLENNIUM MANAGEMENT LLC--
FRANKLIN RESOURCES INC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
Not enough holder history to plot.
Analyst Coverage
Analyst Coverage
Analyst Ratings
4
2
Buy: 4Hold: 2Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$1.34M
8 txns · 1 insider · 46,980 sh
Sells ($, 12mo)
$1.28M
15 txns · 3 insiders · 78,881 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-04-07 | BUY | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 1,108 | $33.38 | $37K | $4.47M |
| 2026-04-07 | SELL | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 8,151 | $31.01 | $253K | $4.16M |
| 2026-04-06 | BUY | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 1,104 | $31.02 | $34K | $4.37M |
| 2026-04-06 | SELL | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 1,259 | $31.06 | $39K | $4.38M |
| 2026-04-02 | BUY | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 2,003 | $35.01 | $70K | $5.08M |
| 2026-04-02 | SELL | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 7,666 | $32.12 | $246K | $4.66M |
| 2026-04-01 | BUY | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 6,175 | $34.49 | $213K | $5.10M |
| 2026-04-01 | SELL | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 1,150 | $31.65 | $36K | $4.68M |
| 2026-03-31 | BUY | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 6,005 | $28.16 | $169K | $4.13M |
| 2026-03-31 | SELL | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 1,591 | $25.49 | $41K | $3.74M |
| 2026-03-30 | SELL | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 888 | $26.61 | $24K | $3.88M |
| 2026-03-30 | BUY | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 9,533 | $25.86 | $246K | $3.77M |
| 2026-03-27 | BUY | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 15,321 | $26.61 | $408K | $3.79M |
| 2026-03-27 | SELL | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 505 | $26.81 | $14K | $3.82M |
| 2026-03-26 | BUY | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 5,731 | $28.62 | $164K | $3.76M |
| 2026-03-26 | SELL | MILLENNIUM MANAGEMENT LLC | 10 percent owner | 1,857 | $28.12 | $52K | $3.69M |
| 2025-12-09 | SELL | Cambrian BioPharma Inc | 10 percent owner | 6,612 | $8.25 | $55K | $1.28M |
| 2025-12-09 | SELL | Peyer James | 10 percent owner, other: See remarks below | 3,507 | $7.96 | $28K | $1.23M |
| 2025-12-08 | SELL | Peyer James | 10 percent owner, other: See remarks below | 3,105 | $8.59 | $27K | $1.36M |
| 2025-12-05 | SELL | Cambrian BioPharma Inc | 10 percent owner | 16,295 | $11.50 | $187K | $1.86M |
Order Flow (FINRA, ~3w lag)
23.8%retail-5.1pp
11.9%dark-4.0pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Sensei Biotherapeutics: A Controlled Demolition Toward Strategic Alternatives
Overall Risk
9/10
Fraud
3/10
Dilution
7/10
Insolvency
10/10
Earnings Overstated
2/10
Hidden Liabilities
5/10
Legal
4/10
Audit Warnings
10/10
Hidden Upside
3/10
Contextually Acceptable
2/10